2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC)
Keyword(s):
2016 ◽
Vol 25
(10)
◽
pp. 2645-2656
◽
Keyword(s):
1998 ◽
Vol 9
(9)
◽
pp. 783-790
◽
Keyword(s):
2019 ◽
Vol 18
(3)
◽
pp. 183-191.e3
◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. e14562-e14562
Keyword(s):